vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and FULTON FINANCIAL CORP (FULT). Click either name above to swap in a different company.
FULTON FINANCIAL CORP is the larger business by last-quarter revenue ($336.2M vs $284.0M, roughly 1.2× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 28.2%, a 68.1% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 4.2%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 0.2%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Fulton Financial Corporation is an American regional financial services holding company, headquartered in Lancaster, Pennsylvania.
ACAD vs FULT — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $336.2M |
| Net Profit | $273.6M | $94.8M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | — |
| Net Margin | 96.3% | 28.2% |
| Revenue YoY | 9.4% | 4.2% |
| Net Profit YoY | 90.3% | 1.9% |
| EPS (diluted) | $1.61 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $336.2M | ||
| Q4 25 | $284.0M | $336.0M | ||
| Q3 25 | $278.6M | $334.6M | ||
| Q2 25 | $264.6M | $324.1M | ||
| Q1 25 | $244.3M | $318.4M | ||
| Q4 24 | $259.6M | $319.6M | ||
| Q3 24 | $250.4M | $317.7M | ||
| Q2 24 | $242.0M | $334.7M |
| Q1 26 | — | $94.8M | ||
| Q4 25 | $273.6M | $99.0M | ||
| Q3 25 | $71.8M | $100.5M | ||
| Q2 25 | $26.7M | $99.2M | ||
| Q1 25 | $19.0M | $93.0M | ||
| Q4 24 | $143.7M | $68.6M | ||
| Q3 24 | $32.8M | $63.2M | ||
| Q2 24 | $33.4M | $95.0M |
| Q1 26 | — | — | ||
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — |
| Q1 26 | — | — | ||
| Q4 25 | 6.1% | 35.7% | ||
| Q3 25 | 12.8% | 38.2% | ||
| Q2 25 | 12.2% | 37.8% | ||
| Q1 25 | 7.9% | 36.1% | ||
| Q4 24 | 59.1% | 27.0% | ||
| Q3 24 | 12.6% | 25.1% | ||
| Q2 24 | 12.6% | 30.8% |
| Q1 26 | — | 28.2% | ||
| Q4 25 | 96.3% | 29.5% | ||
| Q3 25 | 25.8% | 30.0% | ||
| Q2 25 | 10.1% | 30.6% | ||
| Q1 25 | 7.8% | 29.2% | ||
| Q4 24 | 55.4% | 21.5% | ||
| Q3 24 | 13.1% | 19.9% | ||
| Q2 24 | 13.8% | 28.4% |
| Q1 26 | — | $0.55 | ||
| Q4 25 | $1.61 | $0.53 | ||
| Q3 25 | $0.42 | $0.53 | ||
| Q2 25 | $0.16 | $0.53 | ||
| Q1 25 | $0.11 | $0.49 | ||
| Q4 24 | $0.86 | $0.36 | ||
| Q3 24 | $0.20 | $0.33 | ||
| Q2 24 | $0.20 | $0.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $3.5B |
| Total Assets | $1.6B | $32.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $177.7M | — | ||
| Q3 25 | $258.0M | — | ||
| Q2 25 | $253.6M | — | ||
| Q1 25 | $217.7M | — | ||
| Q4 24 | $319.6M | — | ||
| Q3 24 | $155.1M | — | ||
| Q2 24 | $177.1M | — |
| Q1 26 | — | $3.5B | ||
| Q4 25 | $1.2B | $3.5B | ||
| Q3 25 | $917.3M | $3.4B | ||
| Q2 25 | $822.4M | $3.3B | ||
| Q1 25 | $765.2M | $3.3B | ||
| Q4 24 | $732.8M | $3.2B | ||
| Q3 24 | $577.2M | $3.2B | ||
| Q2 24 | $516.7M | $3.1B |
| Q1 26 | — | $32.2B | ||
| Q4 25 | $1.6B | $32.1B | ||
| Q3 25 | $1.3B | $32.0B | ||
| Q2 25 | $1.2B | $32.0B | ||
| Q1 25 | $1.1B | $32.1B | ||
| Q4 24 | $1.2B | $32.1B | ||
| Q3 24 | $976.9M | $32.2B | ||
| Q2 24 | $914.1M | $31.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-48.7M | $304.5M | ||
| Q3 25 | $74.3M | $116.1M | ||
| Q2 25 | $64.0M | $91.7M | ||
| Q1 25 | $20.3M | $703.0K | ||
| Q4 24 | $40.4M | $416.6M | ||
| Q3 24 | $63.2M | $-22.0M | ||
| Q2 24 | $25.0M | $157.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $73.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | -0.18× | 3.08× | ||
| Q3 25 | 1.03× | 1.16× | ||
| Q2 25 | 2.40× | 0.92× | ||
| Q1 25 | 1.07× | 0.01× | ||
| Q4 24 | 0.28× | 6.07× | ||
| Q3 24 | 1.93× | -0.35× | ||
| Q2 24 | 0.75× | 1.66× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
FULT
Segment breakdown not available.
